Navigation Links
Monogram Announces 2008 Third Quarter Financial Results
Date:10/27/2008

Antonio Breast Cancer Symposium in December. Monogram recently announced the initiation of a study in metastatic breast cancer with the Dana Farber Cancer Institute. These and other studies are planned to confirm the initial correlations observed between HERmark measurements and Herceptin response.

"We expect to enhance HERmark during 2009 with clinical data related to Herceptin response upon completion of ongoing and planned clinical studies," added Young. "Also in 2009, our goal is to further expand HERmark with the planned introduction of an additional marker to HERmark that may inform decisions about potential combination therapy, not just Herceptin therapy."

VeraTag(TM) Oncology Platform

"With our VeraTag platform, we can make precise and quantitative measurements of protein complexes that have not previously been possible," said Gordon Parry, Ph.D., Monogram vice president of research & development, oncology. "With an expanding set of EGFR/HER assays, we expect to enhance our current commercially available product, the HERmark Breast Cancer Assay, and also pursue opportunities for use of VeraTag assays in drug development programs in many other cancer types."

Monogram has a growing portfolio of VeraTag assays that measure proteins, protein complexes and post-translational modifications such as phosphorylation, in FFPE tumor samples. This month, Monogram scientists presented data on the HER1 and HER3 total protein assays, the HER1:HER1 homodimer assay and the activated HER1:HER2 heterodimer assay, at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland. Data on the HER2:HER3 heterodimer assay and the HER3:PI3K assay will be presented at the AACR "Targeting the PI3-Kinase Pathway in Cancer" meeting in Cambridge, MA in November. An assay for the truncated form of HER2, known as p95, is in advanced development.

GAAP and Non-GAAP Proforma Results

Net Loss and Net Loss Per Sh
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
10. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Portland, OR (PRWEB) May 06, 2015 ... executive search and growth strategy for the specialty pharmacy ... Sponser of the 2015 Armada Specialty Pharmacy Summit. The ... Wynn Hotel in Las Vegas and is the largest ... people will be in attendance, from pharmacy providers, pharma/biotech ...
(Date:5/5/2015)... Calif. , May 5, 2015  23andMe, Inc., ... of the Lupus Research Study in collaboration ... individuals with systemic lupus erythematosus, more commonly known as ... genetics of lupus. The effort is also in collaboration ... Lupus Awareness Month in May. Approximately 1.5 ...
(Date:5/5/2015)... AVIV, Israel , May 5, 2015 /PRNewswire/ ... the Company was approved to continue trading on ... OTCQB Marketplace allows for a ... electronic broker-dealers. Investors can have real-time quotes and ... The OTCQB Marketplace includes U.S. ...
(Date:5/5/2015)... , May 5, 2015  A group of ... of the Coma Research Institute, a non-profit organization dedicated ... and families suffering from disorders of consciousness.  ... http://photos.prnewswire.com/prnh/20150504/213779LOGO   ... of consciousness, in which no voluntary actions can be ...
Breaking Biology Technology:The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5
... VANCOUVER , July 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ... quarter ended June 30, 2010 . , ... "We are pleased to report continued quarter over quarter ... Products," said Dr. William Hunter , President and CEO of Angiotech. ...
... lend materials new characteristics are generally complicated and therefore ... to astonishment when scientists report on new methods which ... they use economically priced starting materials but also do ... framework made of polystyrene This is exactly ...
... Inc. (Nasdaq: MYL ) today announced that it intends to ... senior notes through a reopening of its Senior Notes due 2020, ... as additional notes under an existing indenture under which Mylan issued ... 2020 on May 19, 2010 . The notes to be ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 2Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 3Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 4Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 5Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 6Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 7Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 8Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 9Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 10Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 11Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 12Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 13Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 14Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 15Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 16Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 17Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 18Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 19Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 20Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 21Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 22Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 23Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 24Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 25Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 26Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 27Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 28Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 29Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 30Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 31Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 32Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 33Empa grows 'sea urchin'-shaped structures 2Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 2Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 3
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/27/2015)... 2015  For more than four decades, AUVSI,s ... the premier worldwide event for the unmanned land, sea, ... event for any local, national, or trade news organization ... markets and current applications of unmanned technologies. The conference ... $48 billion industry, and how it will soon impact ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... in hairy nanoparticles can cheaply and conveniently measure mercury, ... in fluids. Researchers at the Swiss Federal ... of Michigan found that their new method can measure ... at unprecedentedly small concentrations. The system, which could test ...
... Scientists at Mount Sinai School of Medicine have discovered ... properties and resistance to chemotherapy, and participate in tumor ... new tests for early cancer diagnosis, prognostic tests, and ... . Resistance to chemotherapy is a ...
... the German government to transform the energy system and phase ... but much remains to be done. During the course of ... expanded not only through costly offshore facilities, but onshore ... to be tapped, such as in the low mountain ranges," ...
Cached Biology News:Measuring mercury levels: Nano-velcro detects water-borne toxic metals 2Measuring mercury levels: Nano-velcro detects water-borne toxic metals 3Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel' 2More accurate wind energy forecasts 2More accurate wind energy forecasts 3
... Not treated (or medium binding) polystyrene ... binds biomolecules through passive interactions,• Is ... large molecules, such as antibodies, that ... interact with the surface,• Binding capacity ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Material: polystyrene flat ...
... • Reusable, press-to-seal gasket and cover ... and disassembled for hybridizing and imaging thick ... with up to a 13 mm diameter. ... Minimize specimen handling, eliminate evaporation and leaking ...
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
Biology Products: